Figure 7. DRC and SCC exhibit cross resistance to different classes of anti-cancer agents.
(A–E) Hep3B cells, DRC and SCC were plated and treated with different concentration of Paclitaxel, Vinblastine, Methotrexate, Doxorubicin and Cisplatin. After respective drug treatment for 48 h, drug containing medium was replaced and cell survival was evaluated by MTT assay.